<?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/header.php");
?>
    <div class="content">
        <section id="safety-page-banner" class="safety-page-banner">
             <div class="col-xs-12 col-sm-6 col-md-12 col-lg-12">
                            </div>
<div class="row">
            <img src="assets/images/safety.jpg" alt="" class="img-responsive safety-banner" style="position: relative;bottom: 45px;width:100%;"> 
           
       </div>
        
        </section>
		
		 <section id="our-services" class="our-services"style="position: relative; bottom:50px;    margin-top: -1px; ">
                <div class="container">
                    <div class="row">
					  
                         <section id="efficacy-page-table" class="efficacy-page-table">
                             <div class="top-text">
                                <h4 style="font-weight:700;color:#d7006e;line-height: 1.5;position: relative;
   font-size: 23px;left: 100px;" >
                                   Adverse reactions reported in ≥1% of patients receiving XERAVA in controlled  <br>clinical studies<sup>1</sup></h4>
                               <!-- <a href=""><h4 style="margin-left: 159px;color:#d40072">SEE OUR LATEST DEVELOPMENTS > </h4></a> -->
                            </div>
            <img src="assets/images/table.png" alt="" class="img-responsive home-table" style="margin-left: 90px;position:relative; bottom: 32px;">
            <p style="font-weight: 600;
    margin-left: 130px;
    margin-top: 60px;
    font-size: 15px;"><sup>a</sup>XERAVA dose equals 1 mg/kg every 12 hours IV.<br> 
<sup>b</sup>Comparators include ertapenem 1 g every 24 hours IV and meropenem 1 g every 8 hours IV.<br> 
<sup>c</sup>Infusion site reactions include: catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection   <br>    site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling.
</p>
            <div class="image-caption">
                <div class="container">
                    <div class="row">
                        <div class="col-sm-7 col-md-7 col-lg-7">
                           
                            
                        </div>
                    </div>
             
                </div>
            </div>
        </section>

        <div class="panel-group" id="accordion" role="tablist" aria-multiselectable="true">

						 <div class="col-xs-12 col-sm-3 col-md-1 col-lg-1">
					  </div>
                    </div>
                 </div>
                </div>
            </section>

            
         <section>
        <div class="container-fluid" style="background-image: url(assets/images/discover.jpg); background-size:100% ; height:200px;position: relative;
    bottom: 50px; ">
                <h3 style="color:white;text-align:center;margin-top:43px; margin-bottom:20px;font-weight: 700;line-height: 1.5;font-family: politica;">SIMPLE WEIGHT-BASED q12h IV DOSING </h3>
                <button type="button" class="btn btn-danger mybutton btn-sx"><b>LEARN MORE ABOUT DOSAGE</b></button>
                
        </div>
    </section>
<style>
    .mybutton {
  background:none ;
  color: white;
  border: 1px solid white;
  border-radius: 20px;
  margin-left:42%;
  


  
}
button.btn.btn-danger.mybutton {
  outline: none;
}
    </style>

        <!--banner ends -->
     <section id="our-department" class="our-department">
                <div class="container">
               
                    <div class="row">
                        <div class=""style="position: relative;
    bottom: 50px;">
                         
                            <div class="tab-content tab-content col-sm-12 col-md-12 no-padding">
                                <div class="tab-pane active" id="CARDIOLOGY">
                                    <div class="tab-image">
                                        
                                    <p class="" style="font-size:16px;">
                                      AE, adverse event; cIAI, complicated intra-abdominal infection; IV, intravenous; q8h, every 8 hours; q12h, every 12 hours; q24h, every 24 hours.   </p><br>
									   <p style="font-size:16px;"><b>References:</b> 1. XERAVA [prescribing information]. Watertown, MA: Tetraphase Pharmaceuticals, Inc.; 2018.</p><br><br>
									   
									   <p class="blue">
                                       Indications and Usage </p>
                                
                                    <p class="italic">XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: <i>Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium<br> Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in<br> patients</i> 18 years or older.</p><br>
									<p><u>Limitations of Use</u></p>
									<p>
XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).</p><br>
<p class="blue">Usage</p>
<p class="">To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should <br>be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data,<br> local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><br>
<p class="blue">Important Safety Information</p>
<p>XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. <br>Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.</p><br>
<p>The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. </p><br>
<p>The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.</p><br>
<p><i>Clostridium difficile </i>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from <br>mild diarrhea to fatal colitis. </p><br>
<p>The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions (7.7%), nausea (6.5%), and <br>vomiting (3.7%). </p><br>
<p>XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA.  Discontinue XERAVA if any of these adverse reactions are suspected.</p><br>
<p><b>To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</b></p>  
                                </div>
                           
                          
                            </div>
                        </div>
                        <!-- tab content -->
                    </div>
                </div>
            </section>
    </div>
     <?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/footer.php");
?>